2.1
Enzalutamide (Xtandi, Astellas) has a marketing authorisation 'for the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer'.
2 Information about enzalutamide
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
Enzalutamide is administered orally at a dose of 160 mg (4×40 mg soft capsules) daily.
Price
2.3
The price of enzalutamide is £2,734.67 per 112 capsules (excluding VAT; BNF online, accessed December 2018) The daily dose comprises 4 capsules and costs £97.67.
2.4
The company has a commercial arrangement which would apply if the technology had been recommended.